Atrial Fibrillation (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation (Cardiovascular) – Drugs In Development, 2021, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation (Cardiovascular) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 3, 12, 4, 1, 11 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Acesion Pharma Aps

Aetas Pharma Co Ltd

AnaBios Corp

Anthos Therapeutics Inc

ARCA biopharma Inc

Armaron Bio Pty Ltd

Bayer AG

BlueRock Therapeutics LLC

Bristol-Myers Squibb Co

Chaperone Pharma BV

Chong Kun Dang Pharmaceutical Corp

Correvio Pharma Corp

Daiichi Sankyo Co Ltd

Table of Contents

Table of Contents

Introduction

Atrial Fibrillation - Overview

Atrial Fibrillation - Therapeutics Development

Atrial Fibrillation - Therapeutics Assessment

Atrial Fibrillation - Companies Involved in Therapeutics Development

Atrial Fibrillation - Drug Profiles

Atrial Fibrillation - Dormant Projects

Atrial Fibrillation - Discontinued Products

Atrial Fibrillation - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Atrial Fibrillation, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Atrial Fibrillation – Pipeline by AbbVie Inc, 2021

Atrial Fibrillation – Pipeline by Acesion Pharma Aps, 2021

Atrial Fibrillation – Pipeline by Aetas Pharma Co Ltd, 2021

Atrial Fibrillation – Pipeline by AnaBios Corp, 2021

Atrial Fibrillation – Pipeline by Anthos Therapeutics Inc, 2021

Atrial Fibrillation – Pipeline by ARCA biopharma Inc, 2021

Atrial Fibrillation – Pipeline by Armaron Bio Pty Ltd, 2021

Atrial Fibrillation – Pipeline by Bayer AG, 2021

Atrial Fibrillation – Pipeline by BlueRock Therapeutics LLC, 2021

Atrial Fibrillation – Pipeline by Bristol-Myers Squibb Co, 2021

Atrial Fibrillation – Pipeline by Chaperone Pharma BV, 2021

Atrial Fibrillation – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Atrial Fibrillation – Pipeline by Correvio Pharma Corp, 2021

Atrial Fibrillation – Pipeline by Daiichi Sankyo Co Ltd, 2021

Atrial Fibrillation – Pipeline by Espero BioPharma Inc, 2021

Atrial Fibrillation – Pipeline by FB HRS LLC, 2021

Atrial Fibrillation – Pipeline by G3 Pharmaceuticals Inc, 2021

Atrial Fibrillation – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Atrial Fibrillation – Pipeline by HUYA Bioscience International LLC, 2021

Atrial Fibrillation – Pipeline by Hyloris Pharmaceuticals SA, 2021

Atrial Fibrillation – Pipeline by InCarda Therapeutics Inc, 2021

Atrial Fibrillation – Pipeline by Merck & Co Inc, 2021

Atrial Fibrillation – Pipeline by Merz Pharma GmbH & Co KgaA, 2021

Atrial Fibrillation – Pipeline by Milestone Pharmaceuticals Inc, 2021

Atrial Fibrillation – Pipeline by Nissan Chemical Corp, 2021

Atrial Fibrillation – Pipeline by Novartis AG, 2021

Atrial Fibrillation – Pipeline by OMEICOS Therapeutics GmbH, 2021

Atrial Fibrillation – Pipeline by Rhythm Therapeutics Inc, 2021

Atrial Fibrillation – Pipeline by Rithim Biologics Inc, 2021

Atrial Fibrillation – Pipeline by The Geneva Biotech Center SA, 2021

Atrial Fibrillation – Pipeline by Toa Eiyo Ltd, 2021

Atrial Fibrillation – Pipeline by Verseon Corp, 2021

Atrial Fibrillation – Pipeline by Vivasc Therapeutics Inc, 2021

Atrial Fibrillation – Dormant Projects, 2021

Atrial Fibrillation – Dormant Projects, 2021 (Contd..1)

Atrial Fibrillation – Dormant Projects, 2021 (Contd..2)

Atrial Fibrillation – Discontinued Products, 2021

Atrial Fibrillation – Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Atrial Fibrillation, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports